Athira Pharma, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Athira Pharma, Inc.
Biogen/Eisai’s aducanumab, as the first disease-modifying therapy and setting a precedent for accelerated approval, lifted the entire Alzheimer’s field.
In Part 2 of Scrip’s roundtable, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors discuss how the pandemic brought in new investors and triggered strategic shifts for the biopharma industry.
The ways companies found to move forward during the challenging year also offer opportunities for industry to improve. During a roundtable discussion with Scrip, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors weighed in on the adaptations they made and what changes they’ll stick with.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
- Drug Discovery Tools
- Other Names / Subsidiaries
- M3 M3 Biotechnology, Inc.